Dr. Carter T. Davis, MD
Hematology & Oncology (Hematology & Oncology Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 260
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Louisiana State University School of Medicine in Shreveport
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
LA license 305830 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
- Slidell Memorial Hospital Slidell, LA
- Ochsner Medical Center-Hancock Bay Saint Louis, MS
- Ochsner St Anne General Hospital Raceland, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 260
- Services billed
- 958
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 253 | 86 |
| Established patient office or other outpatient visit, 30-39 minutes | 170 | 105 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 118 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 20 | 19 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in New Orleans, LA | 371 |
| Venclexta (venetoclax) | 181 |
| Eliquis (apixaban) Other prescribers in New Orleans, LA | 123 |
| Allopurinol Other prescribers in New Orleans, LA | 92 |
| Prednisone Other prescribers in New Orleans, LA | 90 |
| Hydroxyurea Other prescribers in New Orleans, LA | 69 |
| Gabapentin Other prescribers in New Orleans, LA | 66 |
| Levofloxacin Other prescribers in New Orleans, LA | 61 |
| Olanzapine Other prescribers in New Orleans, LA | 60 |
| Jakafi (ruxolitinib phosphate) | 57 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 37 payments worth $15,895 in total to this clinician.
| Adc Therapeutics America, Inc. | $11,891 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $2,875 |
| AbbVie Inc. | $290 |
| Celgene Corporation | $282 |
| Beone Medicines USA, Inc. | $227 |
| Regeneron Pharmaceuticals, Inc. | $150 |
| Pierre Fabre Pharmaceuticals, Inc. | $52.83 |
| Incyte Corporation | $40.82 |
| Honoraria | $10,500 |
|---|---|
| Consulting Fee | $3,113 |
| Food and Beverage | $1,364 |
| Travel and Lodging | $918 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adc Therapeutics America, Inc. Sep 30, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $10,500 |
| E.r. Squibb & Sons, L.l.c. Jun 4, 2025 | Consulting Fee | $2,875 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $547 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $371 |
| AbbVie Inc. Feb 10, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $238 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $910,173 in research payments for these studies, mostly to the institutions running them.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - Polarix
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.